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OBJECTIVES: Adiponectin is strongly associated with diabetes in the Western population. However, whether 
adiponectin is independently associated with impaired fasting glucose (IFG) in the non-obese population is un-
known. 
METHODS: The serum adiponectin, insulin resistance (IR), and waist circumference (WC) of 27,549 healthy 
Koreans were measured. Individuals were then classified into tertile groups by gender. IFG was defined as a 
fasting serum glucose of 100-125 mg/dL without diabetes. IR was calculated using the homeostasis model as-
sessment of insulin resistance (HOMA-IR). The association of adiponectin and IFG was determined using lo-
gistic regression analysis. 
RESULTS: WC and adiponectin were associated with IFG in both men and women. However, the association 
of WC with IFG was attenuated in both men and women after adjustment for the HOMA-IR. Adiponectin was 
still associated with IFG after adjustment for and stratification by HOMA-IR in men and women. Strong com-
bined associations of IR and adiponectin with IFG were observed in men and women. Multivariate adjusted 
odds ratios (ORs) (95% confidence interval [CI]) among those in the highest tertile of IR and the lowest tertile 
of adiponectin were 9.8 (7.96 to 12.07) for men and 24.1 (13.86 to 41.94) for women. 
CONCLUSION: These results suggest that adiponectin is strongly associated with IFG, and point to adiponec-
tin as an additional diagnostic biomarker of IFG in the non-diabetic population. 
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INTRODUCTION
Diabetes is becoming a growing concern and worldwide health 
problem. According to World Health Organization (WHO) esti-
mates, more than 220 million people worldwide have diabetes 
and an estimated 1.1 million people died from diabetes in 2005 
[1]. Considering this epidemic, it is critical to understand what 
causes diabetes and to explore ways to effectively prevent it. 
Obesity and insulin resistance (IR) have been recognized as 
major risk factors for disease development. As a result, in order 
to predict diabetes, body mass index (BMI) and waist circum-
ference (WC) have been used as obesity indicators. Obesity is 
defined as BMI of ≥25 kg/m² and WC of ≥90 cm for men and 
≥80 cm for women [2]. 
In conjunction with economic growth, the Korean population 
has recently experienced a rapid increase in obesity due to in-
sufficient physical exercise, fast-food diets, and sedentary life-
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styles. According to the Korean National Health and Nutrition 
Examination Survey [3] the mean BMI was 24.0 kg/m² among 
men and 23.1 kg/m² among women, while mean WC was 84.1 
and 78.3 cm for men and women, respectively. Thus, more than 
half of the Korean population is considered non-obese accord-
ing to WHO criteria. However, it is notable that some people 
still suffer from diabetes or impaired fasting glucose (IFG) even 
though their BMI and/or WC are categorized as normal. 
According to a study that included 595 Asian individuals, of 
297 subjects with impaired glucose tolerance (IGT) at baseline, 
35.1% developed diabetes after eight years [4]. In another study, 
cumulative incidences of diabetes in subjects with IFG at base-
line were 16.6% for men and 6.5% for women after four years 
[5]. To identify those at high risk for pre-diabetes several condi-
tions are considered, including family history of diabetes, ex-
cess body weight (high BMI), abdominal adiposity (high WC) 
[6,7], high alcohol intake, and low physical activity [8]. Among 
these factors, BMI and WC have been reported as important 
predictors of IFG [9,10].
In contrast to Caucasians, the majority of Koreans with type 
2 diabetes fall into the non-obese category [11,12] which may 
result in missed opportunities to detect those at a high risk of 
pre-diabetes, as the prevalence of pre-diabetes increases among 
populations with low WC and/or low BMI. Therefore, it is nec-
essary to explore new biomarkers or indicators other than BMI 
or WC, which may help predict the onset of diabetes.
Recently, adiponectin level was introduced as a new indicator 
of obesity. In fact, several studies have reported that adiponec-
tin was associated with diabetes independent of WC and BMI, 
introducing it as a useful marker for metabolic syndrome in type 
2 diabetes in a Korean population [13,14]. Another robust find-
ing identified a positive correlation between adiponectin and 
insulin sensitivity by hyperinsulinemic clamp [15,16] and the 
homeostasis model assessment of insulin resistance (HOMA-IR) 
[17]. It has also been reported that adiponectin is closely relat-
ed to insulin sensitivity, independent of fat mass [16]; however, 
the importance of adiponectin and IR in non-diabetic and non-
obese subjects remains to be elucidated.
The purpose of this study was to investigate the association 
be  tween adiponectin, IR, and IFG among a non-diabetic popu-
lation in Korea and to explore the possibility of using adiponec-




The initial study population consisted of 32,248 subjects who 
participated in the Korean Metabolic Syndrome Research Ini-
tiatives (KMSRI) and volunteered to have routine health exam-
inations at five health promotion centers in university hospitals 
(Severance, Ewha, Seoul National, Korea, and CHA) and one 
private health examination center (Korea Medical Institute) 
from January 2006 to December 2008. After excluding sub-
jects with missing information related to smoking and alcohol 
intake and those with diabetes, data from 27,549 subjects were 
analyzed. The Institutional Review Board of Human Research 
of Yonsei University approved the study and written informed 
consent was obtained from all subjects.
Data collection
Each participant was interviewed using a structured question-
naire to collect history regarding cigarette smoking (never smok-
ed, ex-smoker, current smoker) and alcohol consumption (non-
drinker or drinker of any amount of alcohol), as well as other 
demographic characteristics such as age, gender, and family his-
tory of diabetes. Participants were also asked if they did exer-
cise (exercise, non-exercise). WC was measured midway be-
tween the lower rib and the iliac crest. Weight and height were 
measured while the participants were wearing light clothing. 
BMI was calculated as weight (kg) divided by the square of hei-
ght (m
2). The blood pressure was measured while in the seated 
position by a registered nurse or blood pressure technician us-
ing a standard mercury sphygmomanometer or automatic ma-
nometer. Both systolic and diastolic blood pressures were mea-
sured after a 15 minutes rest.
Measurement of biomarkers
Serum was separated from peripheral venous blood samples 
obtained from each participant after 12 hr of fasting and stored 
at -70˚C prior to clinical chemistry assay. Metabolic syndrome 
biomarkers such as fasting blood glucose (FBG), total cholester-
ol (TC), triglycerides (TG), and high density lipoprotein choles-
terol (HDL-C) were measured using a Hitachi-7600 analyzer 
(Hitachi Ltd., Tokyo, Japan). Adiponectin levels were measured 
in a central laboratory of KMSRI using an enzyme-linked im-
munosorbent assay (ELISA) (Mesdia Co., Ltd., Seoul, Korea). 
The intra- and inter-assay variances for adiponectin were 6.3% 
to 7.4% and 4.5% to 8.6%, respectively [18]. Data quality 
control was conducted in accordance with the procedures of 
the Korean Association of Laboratory Quality Control. IR was 
calculated using the HOMA-IR. HOMA indices were calculated 
as follows: HOMA=fasting insulin (µLU/mL)×fasting glucose 
(mmol/L)/22.5.
Statistical analysis
Age-adjusted prevalence rates for IFG were calculated by di-
rect method to the age distribution of the 2007 Korean adult 
population. Men and women were analyzed separately. The study 3
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samples were divided into tertile groups of WC (<81.0, 81.0-
86.9, ≥87 cm for men; <70, 70-76.9, ≥77 cm for women), BMI 
(<23.1, 23.1-25.3,  ≥25.4 kg/m
2 for men;  <20.9, 20.9-23.2, 
≥23.3 kg/m
2 for women), adiponectin (<4.7, 4.7-7.4, ≥7.4 µg/
mL for men; <7.4, 7.4-11.9, ≥12 µg/mL for women), and HO-
MA-IR (<0.73, 0.73-1.22, ≥1.22 for men; <0.63, 0.63-1.03, 
≥1.03 for women). Multiple logistic regression models were 
used to examine the association of these obesity indicators with 
IFG, after adjusting for age and other potential confounding 
factors, including gender, lifestyle (smoking status, alcohol in-
take, and exercise), HDL-C, family history of diabetes and HO-
MA-IR. Odds ratios (ORs) and 95% confidence intervals (CIs) 
were calculated. Data was analyzed using SAS version 9.0 (SAS 
Inc., Cary, NC, USA). All statistical tests were two-sided and 
statistical significance was determined as p<0.05.
RESULTS
A total of 27,549 subjects (17,180 men and 10,369 women) 
were determined eligible for this study. The mean age was 43.2 
years for men and 42.6 years for women. The mean WC was 
84.1 cm for men and 73.8 cm for women while the mean BMI 
was 24.0 kg/m
2 for men and 22.4 kg/m
2 for women. 
General characteristics of tertile groups of adiponectin are 
presented in Table 1. All variables showed significant differences 
among tertile groups of adiponectin (p<0.001) except age and 
exercise in men and smoking and exercise in women (Table 1).
In the highest tertile groups of WC and BMI, age-adjusted pre-
valence rates of IFG were higher in men than women (18.3% 
and 18.6% in men, 11.1% and 11.0% in women). In the low-
est tertile group of adiponectin, age-adjusted prevalence rates 
of IFG were similar to those in the highest tertile groups of WC 
and BMI (18.8% in men, 11.8% in women) (Tables 2, 3).
After adjusting for age, adiponectin, hypertension, HDL-C, 
family history of diabetes and lifestyle, the ORs (95% CI) for 
IFG in the highest tertiles of WC and BMI compared to those in 
the lowest tertile in men were 1.83 (1.57 to 2.15) and 1.13 
(0.97 to 1.32), respectively. After adjusting for age, WC, BMI, 
hypertension, HDL-C, family history of diabetes and lifestyle, 
the OR (95% CI) for IFG in the lowest tertile of adiponectin 
compared to the highest tertile was 1.87 (1.68 to 2.08) (Table 2, 
Model 1). 
The corresponding ORs (95% CIs) of WC, BMI, and adipo-
nectin in women were 1.60 (1.17 to 2.19), 1.30 (0.96 to 1.75), 
and 2.37 (1.93 to 2.91), respectively (Table 3, Model 1). After 
further adjustment for the HOMA-IR, the OR (95% CI) for IFG 
in the highest tertile of WC compared to the lowest tertile was 
1.31 (1.11 to 1.54) and 1.25 (0.90 to 1.73) in men and women. 
The OR (95% CI) for IFG in the lowest tertile of adiponectin 
compared to the highest tertile was 1.76 (1.58 to 1.97) and 2.17 
(1.76 to 2.68) in men and women (Tables 2, 3, Model 2). After 
further adjustment for the HOMA-IR, the association of WC with 
IFG dis  appeared in women and weakened, but was still signifi-
Table 1. General study population characteristics according to adiponectin level 
Men (n=17,180) Women (n=10,369)
≥7.4 μg/mL 4.7-7.4 μg/mL <4.7 μg/mL
p
≥12 μg/mL 7.4-11.9 μg/mL <7.4 μg/mL
p
Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD Mean±SD
Age (yr) 43.3±10.9 42.9±9.7 43.4±9.0 0.017 41.9±11.3 42.4±10.6 43.5±9.8 <0.001
BMI (kg/m
2) 23.6±2.8 24.4±2.7 25.1±2.7 <0.001 21.7±2.8 22.3±3.0 23.1±3.1 <0.001
WC (cm) 81.9±7.8 84.3±7.4 86.1±7.3 <0.001 71.5±7.6 73.7±7.8 76.1±8.3 <0.001
Systolic BP (mmHg) 121.1±13.3 122.2±13.2 123.7±13.0 <0.001 112.4±14.4 113.2±14.6 115.0±14.7 <0.001
Diastolic BP (mmHg) 76.9±10.3 77.7±10.4 78.7±10.6 <0.001 71.0±9.9 71.7±10.0 72.6±10.5 <0.001
HDL-C (mg/dL) 50.9±9.8 48.7± 9.0 46.9±9.3 <0.001 60.0±11.7 57.3±11.0 54.5±11.0 <0.001
FBG (mg/dL) 87.2±10.3 89.2±10.5 92.1±10.8 <0.001 84.0±8.6 85.7±9.2 88.1±9.6 <0.001
Insulin (μL U/mL) 4.4±2.7 5.0±3.0 5.3±3.3 <0.001 4.0±2.2 4.3±2.5 4.8±2.8 <0.001
HOMA-IR 0.9±0.6 1.1±0.7 1.2±0.8 <0.001 0.8±0.5 0.9±0.6 1.0±0.7 <0.001
% % % % % %
Smoking (yes) 39.2 42.6 44.8 <0.001 4.2 3.9 3.7 0.096
Alcohol drinking (yes) 85.2 87.1 88.4 <0.001 50.6 47.0 45.5 <0.001
Exercise (yes) 63.3 63.9 63.5 0.773 47.6 49.2 48.2 0.403
IFG (yes) 11.9 15.4 22.4 <0.001 4.4 7.4 11.5 <0.001
Hypertension (yes)* 19.8 22.3 25.7 <0.001 10.3 11.7 14.2 <0.001
FH of diabetes (yes) 9.9 13.0 14.9 <0.001 12.9 14.0 17.3 <0.001
FH of hypertension (yes) 14.1 16.2 17.8 <0.001 18.2 19.6 22.4 <0.001
SD, standard deviation; BMI, body mass index; WC, waist circumference; BP, blood pressure; HDL-C, high density lipoprotein cholesterol; FBG, fasting blood 
glucose; HOMA-IR, homeostasis model assessment of insulin resistance; IFG, impaired fasting glucose; FH, family history.
*Hypertension=systolic blood pressure ≥140 mmHg, or diastolic blood pressure ≥90 mmHg, or on medication.4
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cant, in men. However, associations between adiponectin and 
IFG remained significant even after further adjustment for the 
HOMA-IR in both men and women (Tables 2, 3, Model 2). BMI 
was negatively associated with IFG in men (Table 2, Model 2).
Strong combined effects of the IR and adiponectin with IFG 
were observed in both men and women. Multivariate adjusted 
ORs (95% CI) among those in the highest tertile of the HOMA-
IR and the lowest tertile of adiponectin were 9.8 (7.96 to 12.07) 
and 24.1 (13.86 to 41.94) in men and women, when compared 
to those in the lowest tertile of the HOMA-IR and the highest 
tertile of adiponectin, respectively (Figure 1). 
DISCUSSION
Our findings showed that adiponectin and IR were strongly 
associated with IFG in a non-diabetic Korean population. These 
associations were independent of age, smoking status, alcohol 
consumption, exercise, HDL-C, Hypertension, family history of 
diabetes, WC, and BMI. Therefore, these results suggest that adi-
ponectin may be a useful biomarker for diagnosing IFG. 
In the present study, for those in the lowest tertile group of 
WC, the age-adjusted prevalence rates of IFG were substantial-
ly high at 9.0% for men and 7.2% for women. Although WC is 
highly correlated with abdominal obesity, those in the lowest 
Table 2. Multivariable adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for IFG by tertile of WC, BMI, and adiponectin in men
Variables Tertile Level IFG Rate*
Model 1  Model 2
OR 95% CI OR 95% CI
WC (cm) T1 <81.0 543 9.0 1.00 1.00
T2 81.0-86.9 860 13.2 1.42 1.24-1.63 1.18 1.03-1.36
T3 ≥87.0 1,443 18.3 1.83 1.57-2.15 1.31 1.11-1.54
BMI (kg/m
2) T1 <23.1 644 10.2 1.00 1.00
T2 23.1-25.3 938 13.3 0.99 0.86-1.12 0.84 0.73-0.96
T3 ≥25.4 1,264 18.6 1.13 0.97-1.32 0.81 0.69-0.95
Adiponectin (μg/mL) T3 ≥7.4 691 10.3 1.00 1.00
T2 4.7-7.4 869 13.2 1.26 1.13-1.41 1.20 1.07-1.35
T1 <4.7 1,286 18.8 1.87 1.68-2.08 1.76 1.58-1.97
HOMA-IR T1 <0.73 427 6.0 1.00
T2 0.73-1.22 834 12.4 2.23 1.96-2.54
T3 ≥1.22 1,585 25.6 5.72 5.02-6.52
Model 1=Adjusted for age, WC, BMI, adiponectin, hypertension, smoking status, alcohol intake, exercise, HDL-C and FH of diabetes; Model 2=Model 1+  
HOMA-IR.
IFG, impaired fasting glucose; WC, waist circumference; BMI, body mass index; HOMA-IR, homeostasis model assessment of insulin resistance.
*Age adjusted prevalence (%) of IFG.
Table 3. Multivariable adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for IFG by tertile of WC, BMI, and adiponectin in women
Variables Tertile Level IFG Rate*
Model 1  Model 2
OR 95% CI OR 95% CI
WC (cm) T1 <70.0 116 7.2 1.00 1.00
T2 70.0-76.9 206 5.8 1.07 0.81-1.42 0.98 0.73-1.31
T3 ≥77.0 483 11.1 1.60 1.17-2.19 1.25 0.90-1.73
BMI (kg/m
2) T1 <20.9 132 6.4 1.00 1.00
T2 20.9-23.2  199 6.1 0.95 0.72-1.24 0.85 0.64-1.12
T3 ≥23.3 474 11.0 1.30 0.96-1.75 0.91 0.66-1.24
Adiponectin (μg/mL) T3 ≥12 153 4.8 1.00 1.00
T2 7.4-11.9 255 7.9 1.62 1.31-2.01 1.52 1.22-1.90
T1 <7.4 397 11.8 2.37 1.93-2.91 2.17 1.76-2.68
HOMA-IR T1 <0.63 60 2.2 1.00
T2 0.63-1.03 178 5.6 2.94 2.17-3.97
T3 ≥1.03 567 15.9 9.75 7.34-12.95
Model 1=Adjusted for age, WC, BMI, adiponectin, hypertension, smoking status, alcohol intake, exercise, HDL-C and FH of diabetes; Model 2=Model 1+  
HOMA-IR.
IFG, impaired fasting glucose; WC, waist circumference; BMI, body mass index; HOMA-IR, homeostasis model assessment of insulin resistance.
*Age adjusted prevalence (%) of IFG.5
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tertile of WC are hardly considered to be in the high risk group 
for IFG. Similar phenomena such as high-risk individuals being 
‘metabolically obese but normal weight (MONW)’ have been 
previously reported [19]. Hence, the risk of IFG might differ 
according to adiponectin levels in subjects with normal WC. 
Indeed, it has been reported that adiponectin is closely relat-
ed to insulin sensitivity, independent of fat mass [16]. A possible 
role for decreased adiponectin in the pathogenesis of IR was 
provided in a study by Hotta et al. [20] in Rhesus monkeys, 
which reported that plasma levels of adiponectin decreased in 
parallel with the development of IR. Adiponectin also reverses 
IR in animal models of obesity and diabetes [21]. In humans, 
hypoadiponectinemia has been associated with IR [22] and 
longitudinally with an increased risk of type 2 diabetes [23]. 
The glucose-lowering effect of adiponectin has been shown to 
be due in part to its activation of the AMP-activated protein ki-
nase (AMPK) cascade. AMPK, a likely target for metformin and 
other antidiabetic drugs as well as for exercise-related glucose 
transport, is an insulin independent, phylogenetically ancient 
mechanism of stimulating glucose transport [23].
In the present study, both adiponectin and IR were indepen-
dently associated with IFG. If IR was a mediator between adi-
ponectin and IFG, then the association between adiponectin 
and IFG should be attenuated when adjusted for the HOMA-
IR. However, in the present study, the association between adi-
ponectin and IFG was not attenuated. The results reflect the fact 
that both adiponectin and IR may independently contribute to 
the development of IFG in this study population.
Neither WC nor BMI was substantially associated with IFG 
when adiponectin was included in the logistic models (Tables 2 
and 3). In other words, adiponectin was the only significant 
predictor for IFG, and WC and BMI were not. Perhaps para-
doxically, there is some evidence to suggest that omental fat 
may be a more important determinant of circulating adiponec-
tin levels than subcutaneous abdominal fat, as adiponectin is 
secreted from human omental (but not subcutaneous) adipo-
cytes [24]. Therefore, based on the results of the present study, 
the omental fat is more likely associated with adiponectin levels 
than either WC or BMI.
In recent studies, a low plasma adiponectin concentration was 
reported as a sensitive predictor of IFG in the development of 
diabetes [25] and high adiponectin levels were associated with 
a reduced risk of developing diabetes [26,27]. A survey found 
adiponectin provided extra-predictive power beyond obesity 
while leptin did not independently predict the risk of diabetes 
and IFG in older Chinese adults [28]. In the Hoorn study, a high 
adiponectin level was strongly associated with a lower risk of 
impaired glucose metabolism and type 2 diabetes, particularly 
in women [29]. However, only a few studies have investigated 
the association between adiponectin and IFG in those with nor-
mal WC. The present study also further confirmed that there 
were significant combined associations of adiponectin and the 
HOMA-IR with IFG (Figure 1), showing a robust association 
among those in the lowest tertile of adiponectin and highest 
tertile of HOMA-IR. Therefore, adiponectin can be considered 
as an additional marker to detect IFG, especially taken together 
with the HOMA-IR to predict the future onset of diabetes. Of 
course, our results need to be confirmed in future studies using 
cohort groups with IFG.
There are several limitations associated with WC measure-
ments in this study. A high percentage of abdominal fat detect-
ed by computed tomography scan may present as normal WC, 
therefore WC is not a good indicator of abdominal fat. Also, due 
to the cross-sectional study design, it is impossible to assert a 
cause and effect relationship with regards to serum adiponectin 
and IR with IFG. 
Men
HOMA-IR and adiponectin






























Figure 1. Combined association of insulin resistance (IR) assessed by the homeostasis model assessment of insulin resistance (HOMA-IR) 
and adiponectin levels with impaired fasting glucose (IFG) in men and women, expressed as multivariable adjusted odds ratios (ORs). 6
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In conclusion, these results suggest that together, adiponectin 
and the HOMA-IR were strongly associated with IFG, support-
ing adiponectin as an additional marker for diagnosis of IFG. 
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